Medische Oncologie Nummer 6, pp. 49-52
dec 2008, jaargang 11
Medische Oncologie Nr. 6, pp. 49-52
dec 2008, jr. 11
BOM

Herbeoordeling: bevacizumab bij gemetastaseerd colorectaal carcinoom

Lees online

Met inachtneming van eerdere studieresultaten heeft toevoeging van bevacizumab aan standaardchemotherapie beperkte meerwaarde, mits de behandeling langere tijd – dat wil zeggen: tot progressie – kan worden gecontinueerd.

Referenties 

  1. Willemse PHB, Tjan-Heijnen VCG, Bochove A van, et al (NVMOcommissie BOM). Bevacizumab als eerstelijnsbehandeling van het colorectaalcarcinoom. Med Oncol 2005;2:43-5.
  2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
  3. Kabbinavar FF, Schulz J,McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23: 3692-705.
  4. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26: 2013-9.
  5. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX-4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25: 1539-44.
  6. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;33:5326-34.
  7. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008:26;3523-9.
BOM

Herbeoordeling: bevacizumab bij gemetastaseerd colorectaal carcinoom

Lees online

Met inachtneming van eerdere studieresultaten heeft toevoeging van bevacizumab aan standaardchemotherapie beperkte meerwaarde, mits de behandeling langere tijd – dat wil zeggen: tot progressie – kan worden gecontinueerd.

Referenties 

  1. Willemse PHB, Tjan-Heijnen VCG, Bochove A van, et al (NVMOcommissie BOM). Bevacizumab als eerstelijnsbehandeling van het colorectaalcarcinoom. Med Oncol 2005;2:43-5.
  2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
  3. Kabbinavar FF, Schulz J,McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23: 3692-705.
  4. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26: 2013-9.
  5. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX-4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25: 1539-44.
  6. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;33:5326-34.
  7. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008:26;3523-9.
Over dit artikel
Auteur
NVMO-commissie BOM
Printdatum
14 december 2008
E-pubdatum
17 december 2008
ISSN print
1388-2295
ISSN online
2405-4763


Over dit artikel
Auteur
NVMO-commissie BOM
Printdatum
14 december 2008
E-pubdatum
17 december 2008
ISSN print
1388-2295
ISSN online
2405-4763